IQLT - ETF AI Analysis
Top Page
iShares MSCI Intl Quality Factor ETF (IQLT)
IQLT’s rating reflects a portfolio tilted toward financially strong, globally diversified companies, especially in healthcare and technology. High-quality holdings like Novartis, AstraZeneca, and ASML support the fund’s score through solid profitability, growth, and generally positive outlooks, while some names such as Allianz and Zurich Insurance face bearish technical trends that modestly weigh on the rating. The main risk factor is that several top holdings show signs of potential overvaluation or overbought conditions, which could increase volatility if market sentiment shifts.
IQLT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 13.76B
- Region
- Developed Markets
- Expense Ratio
- 0.30%
- Beta
- 0.69
- Issuer
- iShares
- Inception Date
- Jan 13, 2015
- Dividend Yield
- 2.38%
- Asset Class
- Equity
- Index Tracked
- World ex USA Sector Neutral Quality
IQLT Summary
IQLT is the iShares MSCI Intl Quality Factor ETF, which follows the MSCI World ex USA Quality index. It invests in strong, established companies from developed countries outside the U.S., focusing on businesses with steady earnings and solid finances. The fund holds well-known names like Nestlé, Shell, ASML, Roche, and AstraZeneca, spread across many sectors and regions such as Europe and Japan. Someone might invest in IQLT to diversify beyond the U.S. and seek long-term growth from high-quality international companies. A key risk is that its value can still go up and down with global stock markets.
How much will it cost me?
This ETF has an expense ratio of 0.30%, which means you’ll pay about $3 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because it uses a more specialized, rules-based strategy to focus on higher-quality international companies.
What would affect this ETF?
This ETF could benefit if developed markets outside the U.S. experience steady economic growth, supportive interest rate policies, and strong demand for high-quality companies in sectors like technology, health care, and consumer defensive, which include major holdings such as ASML, Nestlé, and Roche. On the other hand, it could face challenges from slower growth or recessions in Europe and Japan, tighter global financial conditions that hurt financial and industrial stocks, or new regulations and geopolitical tensions that weigh on large international firms like Shell and major insurers.
IQLT Top 10 Holdings
IQLT leans heavily on a handful of high‑quality international names, with semiconductor test leader Advantest and chip‑equipment giant ASML acting as key engines of growth, though ASML’s recent wobble has taken a bit of shine off its strong year. Japan’s Recruit Holdings has been quietly rising, adding momentum from the services side, while European health care staples Roche and Novartis provide steady, defensive ballast. Nestlé and Zurich Insurance, both lagging lately, are more like anchors than sails. Overall, the fund is tilted toward developed markets in Europe and Japan, with a notable tech and health care flavor.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 5.17% | $705.13M | EUR 537.83B | 49.49% | 76Outperform |
 DE:ALV | Allianz | 2.69% | $366.98M | EUR 166.78B | 24.90% | 67Neutral |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 JP:6098 | Recruit Holdings Co | 1.87% | $255.32M | JPY 24.91T | 133.13% | 67Neutral |
 GB:SHEL | Shell (UK) | 1.89% | $258.49M | GBP 222.64B | 35.97% | 73Outperform |
 CH:NESN | Nestlé SA | 1.88% | $256.18M | CHF 217.71B | 8.64% | 71Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NOVN | Novartis AG | 1.84% | $250.69M | CHF 240.75B | 32.16% | 80Outperform |
 CH:ZURN | Zurich Insurance Group | 1.85% | $252.20M | CHF 91.77B | 12.64% | 78Outperform |
 JP:6857 | Advantest | 1.91% | $260.04M | JPY 24.95T | 54.61% | 75Outperform |
IQLT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IQLT, the sentiment is Positive. The current price of 50.27 is above the 20-day moving average (MA) of 50.08, below the 50-day MA of 50.36, and above the 200-day MA of 48.81, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 50.96 is Neutral, neither overbought nor oversold. The STOCH value of 66.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IQLT.
IQLT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IQLT | $50.27 | $55.00(9.41% Upside) | $13.76B | 0.30% | 69Neutral |
 VEA | $69.37 | $88.27(27.25% Upside) | $229.60B | 0.03% | 58Neutral |
 SCHF | $26.95 | $33.88(25.70% Upside) | $67.84B | 0.03% | 61Neutral |
 SPDW | $49.26 | $60.37(22.56% Upside) | $40.99B | 0.03% | 61Neutral |
 IDEV | $88.99 | $107.79(21.13% Upside) | $33.86B | 0.04% | 66Neutral |
 AVDE | $88.88 | $108.98(22.61% Upside) | $19.44B | 0.23% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IQLT | iShares MSCI Intl Quality Factor ETF | 50.27 | 7.00 | 16.16% | |
| VEA | Vanguard FTSE Developed Markets ETF | 69.37 | 10.24 | 17.32% | |
| SCHF | Schwab International Equity ETF | 26.95 | 4.06 | 17.73% | |
| SPDW | SPDR Portfolio Developed World ex-US ETF | 49.26 | 7.30 | 17.40% | |
| IDEV | iShares Core MSCI International Developed Markets ETF | 88.99 | 11.31 | 14.55% | |
| AVDE | Avantis International Equity ETF | 88.88 | 12.16 | 15.85% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.